Unknown

Dataset Information

0

Enhancement of HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment with bryostatin-1.


ABSTRACT: The majority of melanoma cells express detectable levels of HLA class II proteins, and an increased threshold of cell surface class II is crucial for the stimulation of CD4+ T cells. Bryostatin-1, a protein kinase C (PKC) activator, has been considered as a potent chemotherapeutic agent in a variety of in vitro tumor models. Little is known about the role of bryostatin-1 in HLA class II Ag presentation and immune activation in malignant tumors, especially in melanoma. In this study, we show that bryostatin-1 treatment enhances CD4+ T cell recognition of melanoma cells in the context of HLA class II molecules. We also show that bryostatin-1 treatment of melanoma cells increases class II protein levels by upregulating the class II transactivator (CIITA) gene. Flow cytometry and confocal microscopic analyses revealed that bryostatin-1 treatment upregulated the expression of costimulatory molecules (CD80 and CD86) in melanoma cells, which could prolong the interaction of immune cells and tumors. Bryostatin-1 also induced cellular differentiation in melanoma cells, and reduced tumorigenic factors such as pro-cathepsins and matrix-metalloproteinase-9. These data suggest that bryostatin-1 could be used as a chemo-immunotherapeutic agent for reducing tumorigenic potential of melanoma cells while enhancing CD4+ T cell recognition to prevent tumor recurrence.

SUBMITTER: Zhao D 

PROVIDER: S-EPMC3196280 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature

altmetric image

Publications

Enhancement of HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment with bryostatin-1.

Zhao Dan D   Amria Shereen S   Hossain Azim A   Sundaram Kumaran K   Komlosi Peter P   Nagarkatti Mitzi M   Haque Azizul A  

Cellular immunology 20110818 2


The majority of melanoma cells express detectable levels of HLA class II proteins, and an increased threshold of cell surface class II is crucial for the stimulation of CD4+ T cells. Bryostatin-1, a protein kinase C (PKC) activator, has been considered as a potent chemotherapeutic agent in a variety of in vitro tumor models. Little is known about the role of bryostatin-1 in HLA class II Ag presentation and immune activation in malignant tumors, especially in melanoma. In this study, we show that  ...[more]

Similar Datasets

| S-EPMC3227386 | biostudies-literature
| S-EPMC2192565 | biostudies-other
| S-EPMC7255108 | biostudies-literature
| S-EPMC6629643 | biostudies-literature
| S-EPMC8320540 | biostudies-literature
| S-EPMC4701504 | biostudies-literature
| S-EPMC9366214 | biostudies-literature
| S-EPMC8741298 | biostudies-literature
| S-EPMC5788343 | biostudies-literature
| S-EPMC4004114 | biostudies-literature